Lexicon Genetics Files Application For LX6171 Phase 1 Trial For Cognitive Disorders

Lexicon Genetics Files Application For LX6171 Phase 1 Trial For Cognitive Disorders: "Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has submitted a Clinical Trial Authorization (CTA) filing to the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for LX6171, an internally- developed small molecule compound for cognitive disorders."